Evidence map›Paper›PMID 42885288›Full record

ReviewOncology reports2026

miR‑324‑5p in oncology: Molecular mechanisms and clinical outlook (Review).

Kun Zhang, Zhen Xu, Yan Bin Luo, Chao Qi Liu, Yong Qin Zhou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kun ZhangThe First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei 443002, P.R. China.
Zhen XuHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei 443002, P.R. China.
Yan Bin LuoHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei 443002, P.R. China.
Chao Qi LiuHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei 443002, P.R. China.
Yong Qin ZhouHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei 443002, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs or miRs) represent a class of regulatory non‑coding RNAs that control post‑transcriptional gene expression and influence multiple cancer‑associated biological processes. Among these molecules, miR‑324‑5p exhibits cancer type‑dependent functions, displaying tumor‑suppressive activity in certain types of malignancy while promoting oncogenic phenotypes in others. The molecular basis responsible for these opposing effects remains to be fully clarified. The present review summarizes evidence and integrates pan‑cancer analyses from The Cancer Genome Atlas to characterize the molecular mechanisms of miR‑324‑5p across different types of malignancies, with emphasis on experimental findings from animal models investigating tumor growth and metastasis. The clinical relevance of miR‑324‑5p, including its diagnostic, prognostic and therapeutic implications, is also discussed, together with challenges limiting clinical translation, particularly tumor‑specific delivery strategies and

Indexed as

Biomarkers, TumorMicroRNAsNeoplasmsAnimalsGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorMicroRNAsMIRN324 microRNA, humanbiomarkercancermicroRNA‑324‑5pmolecular mechanismtherapeutic target

Identifiers

PMID42885288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.